tetano
Editor, Senior Moderator
Viruses
. 2021 Jan 25;13(2):174.
doi: 10.3390/v13020174.
Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
Gordon J Lockbaum[SUP] 1 [/SUP], Archie C Reyes[SUP] 1 [/SUP], Jeong Min Lee[SUP] 1 [/SUP], Ronak Tilvawala[SUP] 1 [/SUP], Ellen A Nalivaika[SUP] 1 [/SUP], Akbar Ali[SUP] 1 [/SUP], Nese Kurt Yilmaz[SUP] 1 [/SUP], Paul R Thompson[SUP] 1 [/SUP], Celia A Schiffer[SUP] 1 [/SUP]
Affiliations
Abstract
Viral proteases are critical enzymes for the maturation of many human pathogenic viruses and thus are key targets for direct acting antivirals (DAAs). The current viral pandemic caused by SARS-CoV-2 is in dire need of DAAs. The Main protease (M[SUP]pro[/SUP]) is the focus of extensive structure-based drug design efforts which are mostly covalent inhibitors targeting the catalytic cysteine. ML188 is a non-covalent inhibitor designed to target SARS-CoV-1 M[SUP]pro[/SUP], and provides an initial scaffold for the creation of effective pan-coronavirus inhibitors. In the current study, we found that ML188 inhibits SARS-CoV-2 M[SUP]pro[/SUP] at 2.5 ?M, which is more potent than against SAR-CoV-1 M[SUP]pro[/SUP]. We determined the crystal structure of ML188 in complex with SARS-CoV-2 M[SUP]pro[/SUP] to 2.39 ? resolution. Sharing 96% sequence identity, structural comparison of the two complexes only shows subtle differences. Non-covalent protease inhibitors complement the design of covalent inhibitors against SARS-CoV-2 main protease and are critical initial steps in the design of DAAs to treat CoVID 19.
Keywords: Covid-19; ML188; Mpro; SARS-CoV-2; crystal structure; direct-acting antivirals; main protease; protease inhibitor; structure-based drug design.
. 2021 Jan 25;13(2):174.
doi: 10.3390/v13020174.
Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
Gordon J Lockbaum[SUP] 1 [/SUP], Archie C Reyes[SUP] 1 [/SUP], Jeong Min Lee[SUP] 1 [/SUP], Ronak Tilvawala[SUP] 1 [/SUP], Ellen A Nalivaika[SUP] 1 [/SUP], Akbar Ali[SUP] 1 [/SUP], Nese Kurt Yilmaz[SUP] 1 [/SUP], Paul R Thompson[SUP] 1 [/SUP], Celia A Schiffer[SUP] 1 [/SUP]
Affiliations
- PMID: 33503819
- DOI: 10.3390/v13020174
Abstract
Viral proteases are critical enzymes for the maturation of many human pathogenic viruses and thus are key targets for direct acting antivirals (DAAs). The current viral pandemic caused by SARS-CoV-2 is in dire need of DAAs. The Main protease (M[SUP]pro[/SUP]) is the focus of extensive structure-based drug design efforts which are mostly covalent inhibitors targeting the catalytic cysteine. ML188 is a non-covalent inhibitor designed to target SARS-CoV-1 M[SUP]pro[/SUP], and provides an initial scaffold for the creation of effective pan-coronavirus inhibitors. In the current study, we found that ML188 inhibits SARS-CoV-2 M[SUP]pro[/SUP] at 2.5 ?M, which is more potent than against SAR-CoV-1 M[SUP]pro[/SUP]. We determined the crystal structure of ML188 in complex with SARS-CoV-2 M[SUP]pro[/SUP] to 2.39 ? resolution. Sharing 96% sequence identity, structural comparison of the two complexes only shows subtle differences. Non-covalent protease inhibitors complement the design of covalent inhibitors against SARS-CoV-2 main protease and are critical initial steps in the design of DAAs to treat CoVID 19.
Keywords: Covid-19; ML188; Mpro; SARS-CoV-2; crystal structure; direct-acting antivirals; main protease; protease inhibitor; structure-based drug design.